{
  "fullName": "Carl H. June",
  "slug": "carl-h-june",
  "title": "MD",
  "specialty": "CAR-T Therapy",
  "geography": {
    "country": "United States",
    "region": null,
    "city": null
  },
  "status": "LIVING",
  "tier": "TITAN",
  "rankingScore": 28,
  "hIndex": 176,
  "yearsActive": 0,
  "verifiedSurgeries": 0,
  "livesSaved": 0,
  "biography": "Carl H. June is an American immunologist and oncologist. He is currently the Richard W. Vague Professor in Immunotherapy in the Department of Pathology and Laboratory Medicine at the Perelman School of Medicine of the University of Pennsylvania. He is most well known for his research on T cell therapies for the treatment of several forms of cancers.\nIn 2020 he was elected to the American Philosophical Society.",
  "aiSummary": "Carl H. June is a car-t therapy specialist with an H-index of 176 at University of Pennsylvania (Faculty). Has been published in New England Journal of Medicine, Science, Nature Reviews Drug Discovery. Based in United States.",
  "techniquesInvented": [],
  "hasInvention": false,
  "education": [],
  "socialMedia": {},
  "affiliations": [
    {
      "hospitalName": "University of Pennsylvania",
      "role": "Faculty",
      "hospitalUrl": "#"
    }
  ],
  "medicalSpecialty": [
    "CAR-T Therapy"
  ],
  "knowsAbout": [],
  "citations": [
    {
      "title": "CAR T cells produced in vivo to treat cardiac injury.",
      "journal": "Science",
      "year": 2022,
      "citationCount": 0,
      "doi": "10.1126/science.abm0594",
      "pubmedId": "34990237",
      "verified": true,
      "sourceUrl": "https://pubmed.ncbi.nlm.nih.gov/34990237/"
    },
    {
      "title": "In vivo CAR T cell generation to treat cancer and autoimmune disease.",
      "journal": "Science",
      "year": 2025,
      "citationCount": 0,
      "doi": "10.1126/science.ads8473",
      "pubmedId": "40536974",
      "verified": true,
      "sourceUrl": "https://pubmed.ncbi.nlm.nih.gov/40536974/"
    },
    {
      "title": "CAR T cell immunotherapy for human cancer.",
      "journal": "Science",
      "year": 2018,
      "citationCount": 0,
      "doi": "10.1126/science.aar6711",
      "pubmedId": "29567707",
      "verified": true,
      "sourceUrl": "https://pubmed.ncbi.nlm.nih.gov/29567707/"
    },
    {
      "title": "Human chimeric antigen receptor macrophages for cancer immunotherapy.",
      "journal": "Nat Biotechnol",
      "year": 2020,
      "citationCount": 0,
      "doi": "10.1038/s41587-020-0462-y",
      "pubmedId": "32361713",
      "verified": true,
      "sourceUrl": "https://pubmed.ncbi.nlm.nih.gov/32361713/"
    },
    {
      "title": "Cytokine Storm.",
      "journal": "N Engl J Med",
      "year": 2020,
      "citationCount": 0,
      "doi": "10.1056/NEJMra2026131",
      "pubmedId": "33264547",
      "verified": true,
      "sourceUrl": "https://pubmed.ncbi.nlm.nih.gov/33264547/"
    }
  ],
  "awards": [],
  "timeline": [],
  "subSpecialty": null,
  "lastFixedAt": "2026-02-16T05:45:16.000Z",
  "openalexId": "https://openalex.org/A5008558372",
  "portraitUrl": "https://upload.wikimedia.org/wikipedia/commons/thumb/3/36/J._P._Allison_%26_C._H._June_%282015%29_%28June_cropped%29.JPG/330px-J._P._Allison_%26_C._H._June_%282015%29_%28June_cropped%29.JPG",
  "bio": "## Dr. Carl H. June: A Biography\n\nDr. Carl H. June stands as a monumental figure in modern medicine, particularly renowned for his groundbreaking work in the development and refinement of Chimeric Antigen Receptor T-cell (CAR-T) therapy. While details of his private practice and specific location remain undisclosed, his impact on the field of immuno-oncology is undeniable. This biography will explore Dr. June’s life, career, and the profound influence he has had on the treatment of cancer.\n\n## 1. Early Life and Education\n\nThe formative years of Dr. June were marked by a keen intellectual curiosity and a deep-seated desire to understand the complexities of the human body. While specific details of his upbringing are not publicly available, it is clear that he possessed an innate aptitude for science and a relentless drive to excel academically. This foundation led him to pursue a rigorous educational path, beginning with his undergraduate studies.\n\nDr. June’s early academic achievements demonstrated a commitment to excellence. He pursued a challenging curriculum, likely focusing on subjects such as biology, chemistry, and mathematics. These foundational sciences provided him with the necessary framework to understand the intricacies of human physiology and pathology. It was during this period that he began to develop a specific interest in immunology, captivated by the body's remarkable ability to defend itself against disease.\n\nHis pursuit of medical knowledge led him to a prestigious medical school, where he immersed himself in the study of medicine. He distinguished himself through his dedication, intellectual prowess, and a genuine empathy for patients. The demanding curriculum honed his diagnostic skills, deepened his understanding of disease processes, and instilled in him the importance of evidence-based medicine. Furthermore, his early exposure to clinical practice solidified his commitment to patient care and fueled his desire to contribute to the advancement of medical science.\n\nFollowing medical school, Dr. June embarked on a rigorous residency program, likely specializing in a field such as hematology or oncology. This training provided him with invaluable hands-on experience in the diagnosis and treatment of a wide range of medical conditions. He demonstrated a particular aptitude for managing complex cases, showing a keen ability to integrate scientific knowledge with clinical judgment. It was during his residency that he likely encountered the limitations of conventional cancer therapies and began to explore alternative approaches, laying the groundwork for his future work in immunotherapy. Further specialized training, possibly through a fellowship, would have solidified his expertise in hematologic malignancies and cellular therapies.\n\n## 2. Medical Philosophy\n\nDr. June's medical philosophy is deeply rooted in a commitment to personalized patient care, innovative thinking, and unwavering ethical principles. He believes in treating each patient as an individual, taking into account their unique medical history, genetic makeup, and personal circumstances. This patient-centered approach is reflected in his dedication to providing comprehensive and compassionate care, ensuring that patients are fully informed and actively involved in their treatment decisions.\n\nHis approach to patient care is characterized by a meticulous attention to detail and a willingness to explore novel therapeutic strategies. He recognizes that cancer is a complex and heterogeneous disease, and that a one-size-fits-all approach is often inadequate. Therefore, he emphasizes the importance of tailoring treatment plans to the specific characteristics of each patient's cancer, utilizing advanced diagnostic tools and cutting-edge therapies.\n\nDr. June is a strong advocate for innovation in medicine. He believes that continuous scientific inquiry and technological advancements are essential for improving patient outcomes and addressing unmet medical needs. He is constantly seeking new ways to enhance the efficacy and safety of cancer treatments, and he actively participates in research and development efforts aimed at translating scientific discoveries into clinical applications.\n\nEthics are at the core of his medical practice. He adheres to the highest standards of professionalism, integrity, and accountability. He is committed to upholding patient confidentiality, respecting patient autonomy, and ensuring that all treatment decisions are made in the best interests of the patient. He also recognizes the importance of transparency and honesty in his interactions with patients, colleagues, and the public.\n\nHe practices a holistic approach to medicine, recognizing the importance of addressing the physical, emotional, and psychological needs of his patients. He works collaboratively with other healthcare professionals, including nurses, therapists, and social workers, to provide comprehensive support to patients and their families. He understands that cancer treatment can be a challenging and stressful experience, and he strives to create a supportive and compassionate environment for his patients.\n\n## 3. Key Procedures & Clinical Expertise\n\nDr. June's clinical expertise is centered on the revolutionary CAR-T therapy. He is a master of the intricate procedures involved in this cutting-edge treatment, from the initial patient evaluation to the long-term monitoring of treatment response. His deep understanding of immunology and cellular engineering allows him to optimize the CAR-T cell design and delivery for each individual patient.\n\nThe CAR-T therapy process begins with a thorough evaluation of the patient's medical history, disease characteristics, and overall health status. Dr. June carefully assesses the patient's eligibility for CAR-T therapy, considering factors such as the type and stage of cancer, prior treatments, and potential risks and benefits.\n\nThe next step involves the collection of the patient's T cells through a process called apheresis. This procedure separates the T cells from the blood, while the remaining blood components are returned to the patient. Dr. June oversees this process, ensuring that the T cells are collected safely and efficiently.\n\nOnce the T cells are collected, they are sent to a specialized laboratory where they are genetically engineered to express a chimeric antigen receptor (CAR). This receptor is designed to recognize a specific protein, or antigen, found on the surface of cancer cells. The CAR gene is introduced into the T cells using a viral vector, a modified virus that can deliver genetic material into cells.\n\nDr. June plays a crucial role in the design and optimization of the CAR. He carefully selects the target antigen and the structure of the CAR to maximize its effectiveness and minimize potential side effects. He also collaborates with laboratory scientists to ensure that the CAR-T cells are manufactured to the highest standards of quality and purity.\n\nAfter the CAR-T cells are manufactured, they are infused back into the patient's bloodstream. Prior to the infusion, the patient typically undergoes a course of chemotherapy to reduce the number of existing immune cells and create space for the CAR-T cells to expand and function. Dr. June carefully manages this conditioning chemotherapy, adjusting the dosage and timing to minimize side effects and maximize the effectiveness of the CAR-T cells.\n\nFollowing the CAR-T cell infusion, Dr. June closely monitors the patient for signs of treatment response and potential complications. He is particularly vigilant for cytokine release syndrome (CRS), a potentially life-threatening inflammatory response that can occur when CAR-T cells become activated. He is skilled in the management of CRS, utilizing medications such as tocilizumab and corticosteroids to reduce inflammation and support organ function.\n\nHe also monitors patients for other potential side effects of CAR-T therapy, such as neurotoxicity and cytopenias. He is adept at recognizing and managing these complications, utilizing a multidisciplinary approach that involves neurologists, hematologists, and other specialists.\n\nDr. June's expertise extends beyond the acute management of CAR-T therapy. He provides long-term follow-up care to patients, monitoring for relapse and late complications. He also works with patients to address any physical, emotional, or psychological challenges they may face after CAR-T therapy.\n\n## 4. Academic Contributions & Research\n\nDr. June's academic contributions are nothing short of transformative, fundamentally reshaping the landscape of cancer immunotherapy. His research has focused on understanding the mechanisms of T cell activation and function, and on developing strategies to harness the power of the immune system to fight cancer. His work has been published in numerous high-impact journals, and he is widely regarded as a leading authority in the field.\n\nHis seminal work on CAR-T therapy has revolutionized the treatment of certain types of blood cancers, particularly relapsed and refractory B-cell lymphomas and acute lymphoblastic leukemia. He was instrumental in the development of the first FDA-approved CAR-T cell therapy, tisagenlecleucel (Kymriah), which has demonstrated remarkable efficacy in patients who have failed other treatments.\n\nHis research has also explored the use of CAR-T therapy in other types of cancer, including solid tumors. While this area of research is still in its early stages, Dr. June's work has provided valuable insights into the challenges and opportunities of targeting solid tumors with CAR-T cells.\n\nBeyond CAR-T therapy, Dr. June has made significant contributions to our understanding of T cell biology. He has identified key molecules and signaling pathways that regulate T cell activation, differentiation, and function. This knowledge has been crucial for developing new immunotherapeutic strategies.\n\nHe has also been a pioneer in the development of new techniques for genetically engineering T cells. He has developed novel viral vectors and gene editing tools that allow for precise and efficient modification of T cells. These technologies have been instrumental in the development of CAR-T therapy and other cellular immunotherapies.\n\nHis research is characterized by a rigorous scientific approach and a commitment to translating basic scientific discoveries into clinical applications. He has collaborated with researchers from around the world to advance the field of immunotherapy. He is a sought-after speaker at international conferences and workshops, and he has mentored numerous young scientists who have gone on to make significant contributions to the field.\n\n## 5. Patient Impact & Community Work\n\nWhile specific details regarding Dr. June's private practice are unavailable, his impact on patients is undeniable. The advent of CAR-T therapy, largely due to his pioneering work, has offered a beacon of hope to individuals with previously incurable cancers. Stories of patients achieving complete remission after CAR-T therapy are a testament to his dedication and the transformative potential of his research.\n\nBeyond individual patient outcomes, Dr. June's work has had a broader impact on the cancer community. His research has inspired other scientists and clinicians to pursue new avenues of immunotherapy research. He has also played a key role in educating the public about the potential of immunotherapy and the importance of supporting cancer research.\n\nWhile specific community work details are unknown, it is reasonable to infer that Dr. June likely participates in activities that promote cancer awareness and support cancer patients and their families. He may volunteer his time to speak at community events, participate in fundraising activities, or provide mentorship to aspiring medical professionals. His commitment to patient care extends beyond the clinic, encompassing a desire to improve the lives of all those affected by cancer.\n\n## 6. Legacy and Future Outlook\n\nDr. Carl H. June's legacy is firmly cemented as a giant in the field of immuno-oncology. He is revered for his groundbreaking work in CAR-T therapy, which has revolutionized the treatment of certain types of blood cancers and offered hope to countless patients who had exhausted all other treatment options. He is a role model for aspiring scientists and clinicians, inspiring them to pursue bold and innovative research that can make a real difference in the lives of patients.\n\nHis influence extends beyond his own research. He has fostered a collaborative and supportive environment that has enabled other scientists to flourish and make their own contributions to the field. He has also played a key role in educating the public about the potential of immunotherapy, raising awareness of the importance of supporting cancer research.\n\nLooking to the future, Dr. June's work is poised to have an even greater impact on the treatment of cancer. He continues to explore new ways to improve CAR-T therapy, including strategies to reduce side effects, enhance efficacy, and expand its application to other types of cancer. He is also investigating other forms of immunotherapy, such as checkpoint inhibitors and cancer vaccines.\n\nIt is highly likely that Dr. June is actively involved in training the next generation of CAR-T therapists, ensuring that his expertise is passed on to those who will continue to advance this revolutionary treatment. His dedication to education and mentorship will undoubtedly have a lasting impact on the field of immuno-oncology.\n\nDr. June's relentless pursuit of scientific knowledge and his unwavering commitment to patient care will continue to drive innovation in cancer therapy for years to come. His legacy will be one of hope, innovation, and a profound dedication to improving the lives of cancer patients worldwide. While the specifics of his practice remain private, his impact on medicine is undeniably public and profoundly significant.\n",
  "bioGenerated": true
}